PolyNovo (ASX:PNV) has reached a stage in its medical device development where the focus extends beyond product adoption to Manufacturing efficiency and broader commercial opportunities. FY2026 delivered another year of Revenue growth and the completion of a new manufacturing facility, while gross Margin declined and statutory profit was lower than the previous year. Investors following the stock this September have several operating factors to consider.

Latest Development

PolyNovo released its FY2026 results on 25 August 2026, covering the year to 30 June 2026. Total revenue reached A$150.0 million, 16.1% higher than FY2025, with commercial sales of A$138.4 million increasing 16.7%, or 21.3% on a constant currency basis.

Net profit after tax was A$7.3 million, 44.4% lower than the prior year, while gross margin declined to 89.0% from 95.6%. Reported EBITDA was A$12.1 million, increasing 8.1%, while underlying EBITDA reached A$13.4 million.

Company Overview

PolyNovo develops and sells medical devices based on its proprietary NovoSorb bioabsorbable polymer technology. Its lead product, NovoSorb BTM, is a biodegradable temporary matrix used in the treatment of burns and complex wounds. Other products include NovoSorb MTX and SynPath, which extend the platform into additional clinical applications.

Revenue is generated across multiple geographic markets. The Americas contributed A$104.1 million in FY2026, while EMEA contributed A$20.6 million and APAC contributed A$13.7 million. The company continued expanding its commercial operations across these regions.

What Investors May Watch Next

Regulatory progress in the United States remains an important area to monitor. The company has identified regulatory submissions and expansion of clinical applications as key priorities for FY2027.

Growth outside traditional burn applications is another area of interest, with the company continuing to develop additional uses for its technology platform. The commercial rollout of NovoSorb SynPath into outpatient settings and further development of Business opportunities may influence future growth.

The appointment of Dr Marthe D'Ombrain as Chief Scientific Officer also reflects continued focus on scientific and clinical development.

Risks

The decline in gross margin remains an important consideration, and transitioning production into a new manufacturing Facility involves execution and validation requirements that may affect costs. Regulatory timelines in the United States remain subject to external approval processes.

Revenue remains concentrated around the NovoSorb technology platform, while foreign currency movements can affect reported financial outcomes due to international sales exposure.

Bottom Line

PolyNovo enters the remainder of 2026 with revenue growth, a completed manufacturing facility and ongoing development of additional applications for its NovoSorb platform. FY2026 showed higher sales alongside lower statutory Earnings and reduced gross margins.

The next stage for the company will depend on manufacturing performance, regulatory progress and commercial expansion across existing and new clinical applications.